NASDAQ: NDRAEndra Life Sciences Inc Stock
$5.04-0.29 (-5.44%)
Updated Jul 1, 2026
NDRA Price
$5.04
Fair Value Price
$0.34
Market Cap
$6.40M
52 Week Low
$2.96
52 Week High
$11.96
P/E
-0.62x
P/B
3.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.92
Operating Cash Flow
-$5M
Beta
1.14
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NDRA Overview
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NDRA's potential to beat the market
- NDRA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
NDRA
RankedUnranked of 44
RankedUnranked of 44
Be the first to know about important NDRA news, forecast changes, insider trades & much more!
NDRA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NDRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NDRA ($5.04) is overvalued by 1,369.03% relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NDRA ($5.04) is not significantly undervalued (1,369.03%) relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NDRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NDRA due diligence checks available for Premium users.
Valuation
NDRA fair value
Fair Value of NDRA stock based on Discounted Cash Flow (DCF)
Price
$5.04
Fair Value
$0.34
Overvalued by
1,369.03%
NDRA ($5.04) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NDRA ($5.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NDRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NDRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.62x
Industry
12.54x
Market
8.54x
NDRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.58x
Industry
3.87x
NDRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NDRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.3M
Profit Margin
0%
NDRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.4M
Liabilities
$1.7M
Debt to equity
0.92
NDRA's short-term liabilities ($835.44k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NDRA's long-term liabilities ($815.86k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NDRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NDRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$450.0k
Financing
$263.7k
NDRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NDRA vs Diagnostic & Research Stocks
Endra Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.